Every 10-Q that C4 Therapeutics, Inc. (CCCC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CCCC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CCCC filings page.
C4 Therapeutics reported unaudited results for the quarter ended June 30, 2026, remaining a clinical-stage company with no product sales and revenues derived from collaborations. Revenue from collaboration agreements was $6.6 million in the quarter and $12.8 million for the first half of 2026.
The company recorded a quarterly net loss of $23.6 million and a six‑month net loss of $48.8 million, with operating expenses driven mainly by research and development of its degrader pipeline, including lead program cemsidomide for multiple myeloma and CFT8919 for EGFR‑mutant lung cancer.
Liquidity remains strong, with $300.4 million in cash, cash equivalents, and marketable securities and total assets of $359.4 million as of June 30, 2026. Management states this resource base is expected to fund operations for at least twelve months. A new Roche degrader‑antibody conjugate collaboration added a $20.0 million upfront payment and significant potential milestones and royalties, supplementing existing partnerships with MKDG, Betta Pharma, Roche, Biogen, and Pfizer.
C4 Therapeutics reported a first‑quarter 2026 net loss of $25.1 million, slightly improved from $26.3 million a year earlier, as collaboration revenue was $6.2 million and operating expenses eased modestly. Cash, cash equivalents and marketable securities totaled $268.3 million as of March 31, 2026, which management believes will fund operations for at least 12 months.
The company continues to focus on targeted protein degradation, advancing lead drug cemsidomide in multiple myeloma through a Phase 2 trial and a Phase 1b combination study with elranatamab. Lung cancer candidate CFT8919 is in Phase 1 in Greater China via Betta Pharma. Collaborations with Roche, Biogen, Betta Pharma and MKDG provided milestone and research revenue, including a $2.0 million Biogen milestone in the quarter, and a new April 2026 Roche DAC agreement added a $20.0 million upfront payment and more than $1.0 billion in potential milestones.
C4 Therapeutics (CCCC) filed its Q3 2025 10‑Q, reporting collaboration revenue of $11.23 million and a net loss of $32.17 million. Revenue declined year over year as milestone and services mix shifted, while expenses rose on a $10.73 million non‑cash impairment tied to a new sublease, bringing total operating expenses to $45.64 million. Interest and other income contributed $2.25 million.
Cash, cash equivalents and marketable securities were $199.8 million as of September 30, 2025. The company sold 2,950,225 shares via its at‑the‑market program for $7.5 million in net proceeds and later terminated the ATM sales agreement. Shares outstanding were 74,174,515 as of September 30, 2025.
Collaboration updates include a Clinical Trial Collaboration and Supply Agreement with Pfizer under which Pfizer will supply elranatamab at no cost for a planned Phase 1b multiple myeloma study; C4T will sponsor and fund the trial, and the parties will jointly own clinical data. Merck provided notice to terminate the DAC collaboration effective late November 2025; the $10.0 million upfront tied to that program has been fully recognized. C4T also recorded a $2.0 million Biogen milestone in September and previously added $4.0 million in Roche milestones in March.
C4 Therapeutics (NASDAQ: CCCC) Q2 2025 10-Q highlights
- Revenue: $6.5 m from collaborations, down 46 % YoY (Q2 24: $12.0 m) as Biogen–related income rolled off.
- Expenses: R&D $26.2 m (+10 % YoY); G&A $8.8 m (-10 % YoY). Total op-ex $35.0 m (+4 %).
- Losses: Operating loss widened to $28.5 m; net loss $26.0 m (-$0.37 pps) versus $17.7 m (-$0.26 pps) a year ago. 1H 25 net loss $52.3 m.
- Cash runway: Cash, cash equivalents & marketable securities were $223 m at 6-30-25 (vs. $267 m at 12-31-24); management projects ≥12-month runway.
- Balance sheet: Deferred revenue $43.8 m, reflecting future work under Roche, MKDG, Merck and Betta deals; no debt.
- Collaboration momentum: Earned $1 m discovery milestone (MKDG) and two $2 m lead-series milestones (Roche). Q2 revenue mix: MKDG 53 %, Roche 30 %, Merck 16 %, Betta 1 %.
- Share count: 71.2 m outstanding (7-29-25) after equity comp and ESPP; authorized shares doubled to 300 m.
- Guidance & risk: Company remains clinical-stage with no product sales; relies on external funding and partner milestones; accumulated deficit $686 m.
The filing affirms strategic focus on protein-degrader oncology programs (e.g., CFT8919, DACs) while controlling G&A. Near-term catalysts hinge on progress within partnered pipelines and internal Phase 1 assets.